Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Hematologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
June 19, 2008
Melanoma: The Holy Grail at Last??
Analysis of: Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1 | content.nejm.org
Author: GLG Expert Contributor
"In summary, THEY showed that the infusion of a clonal population of CD4+ T cells with specificity for a single tumor-associated antigen caused complete regression of a tumor. During regression of the tumor, this clone appears to have induced the patient's own T cells to respond to other antigens of...
June 11, 2008
Targeted therapy for myeloproliferative disorders (MPD) from Cephalon
Analysis of: Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders | bloodjournal.hematologylibrary.org
Author: GLG Expert Contributor
Very preliminary but this agent may offer a targeted, more "natural" approach to the MPD's- Polycythemia Vera, Myelofibrosis and Primary thrombocytosis.
June 9, 2008
Transgene's vaccine for SCLC: Promising, BUT need to await survival and Phase III data
Analysis of: Transgene's Therapeutic Vaccine TG4010 Meets Primary Endpoint in Non-Small Cell Lung Cancer Phase IIb Trial | www.pipelinereview.com
Author: GLG Expert Contributor
Tarnsgene's cancer vaccine TG 4010 increased response rates and progression free survival when added to chemotherapy in patients with advanced small cell lung cancer. The overall survival rates and time to progression were not much different in the 2 treatment groups. The vaccine is novel and efficacy...
June 9, 2008
Diabetes: Let's avoid pseudoscience and start over.....
Analysis of: Tight Rein on Blood Sugar Has No Heart Benefit | www.nytimes.com
Author: GLG Expert Contributor
Tight Glucose control in type 2 diabetes mellitus did not result in improved survival and possibly had a negative impact.
June 5, 2008
Trovax for renal cell carcinoma: not much potential
Analysis of: Sanofi-Aventis and Oxford Biomedica report encouraging Trovax(R) phase II trial results in Metastatic Renal Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
The efficacy of the immunotherapeutic" vaccine" Trovax in 3 separate small phase II trials in combination with interferon alpha or IL-2 was modest at best. With availability of 3 targeted agents for this disease ( Nexavar, Sutent, and Torisel) , the chances of such as an agent are very limited.
June 4, 2008
Trovax(R) Sanofi-Aventis and Oxford Biomedica: Interesting but.....
Analysis of: Sanofi-Aventis and Oxford Biomedica report encouraging Trovax(R) phase II trial results in Metastatic Renal Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
This immunotherapeutic agent in association with interleukin 2 or interferon may be effective in renal cell carcinoma (RCC). To be tested in a phase III trial (against what??)
June 4, 2008
ASA404 in a phase III trial in lung cancer?? "A crap shoot?"
Analysis of: Positive data on Antisoma’s ASA404 presented at ASCO | www.pipelinereview.com
Author: GLG Expert Contributor
That appears to be a well contructed phase III trial adds ASA404 or a placebo to Taxol/Carboplatin. Nothing exotic, endpoints are overall survival (OS) as well as OS in Squams and non Squams.
June 2, 2008
A New Algorithm Will be Needed to Calculate Market Sharee
Analysis of: Genetic Research May Help Pick Patients' Best Cancer Drugs | online.wsj.com
Author: GLG Expert Contributor
Genetic profiling will tell us who should or should not receive particular anti neoplastic agents. This is "personalized" therapy that has been predicted x years.
June 2, 2008
Chinese generics: Low prices bu qulaity reputation will favor India
Analysis of: China Muscles In On The Generics Industry | www.pharmalot.com
Author: GLG Expert Contributor
China, buoyed by its recent economic boom, is invading industrilaized nation markets with many generic compounds , from pain killers to AIDS drugs. Chinese drugs are cheap, but have reputation for poor quality , especially with recent heparin fiasco. India has had a good track record with generics and...
June 2, 2008
ImClone: One study shot down. The other??
Analysis of: Drug Brings ImClone in From Cold | online.wsj.com
Author: GLG Expert Contributor
Well we know that the lung cancer trial  http://online.wsj.com/article/SB121227163771635641.html?mod=2_1566_topbox was a bust so far. What other "good news" do we await

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next81 to 90 of 701

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T13:45:22.747